Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566338 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4302814 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT07566338: Recruiting Phase 1 study, sponsored by Eli Lilly and Company.
NCT07566338 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 150 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07566338, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 6 months and will include at least one overnight stay in the clinical research unit (CRU) lasting up to approximately 9 days.
Interventions
- DRUG Placebo
- DRUG LY4302814
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT07566338 shows while recruiting
NCT07566338 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07566338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07566338 about?
NCT07566338 is a clinical study titled "A Study of LY4302814 in Healthy Participants". The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last a...
What is the current status of trial NCT07566338?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2026-05-06. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07566338?
The interventions under investigation include: Placebo (DRUG), LY4302814 (DRUG).
Who is sponsoring clinical trial NCT07566338?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07566338's enrollment target sits among peer trials
150 363rd of 2000 higher than 1,620 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI